Literature DB >> 36225628

Prediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.

Xuyong Wei1,2, Wentao Xie1,3,2, Weiwei Yin4, Mengfan Yang1,3,2, Abdul Rehman Khan1,3,2, Renyi Su1,2, Wenzhi Shu1,2, Binhua Pan1,3,2, Guanghan Fan1,3,2, Kun Wang1,3,2, Fan Yang1,2, Di Lu1,2, Changbiao Li1,2, Linhui Pan1,2, Beini Cen1,2, Haiyang Xie3,2, Li Zhuang5, Shusen Zheng3,2,5, Xun Zeng6,7, Wei Chen4,8,9,7, Xiao Xu1,2,10.   

Abstract

Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a marker of poor prognosis. However, the reliable biomarkers of post-LT HCC recurrence remain to be identified. In this study, serial peripheral blood samples from the LT recipients with and without HCC recurrence were collected at five time points. Single-cell mass cytomertry (CyTOF) was utilized for the in-depth analysis of peripheral blood monocellular cells (PBMCs). CyTOF analysis showed that at 3 weeks post-LT, the activated immune cell population was increased, while the fraction of immune cells with suppressive functions (myeloid-derived suppressive cells) was reduced. The post-LT immune composition in patients with LT for HCC was enormously different from that in patients with LT for causes other than HCC. Furthermore, at 3 weeks after LT, compared with patients without recurrence, the patients with HCC recurrences were high in two subsets of T cells: CD57+ HLA-DR+ CD8+ and CD28+γδ. The CD57+ HLA-DR+ CD8+ T cells presented high levels of perforin, granzyme B, and Ki-67 and displayed a highly cytotoxic and proliferative phenotype, while the CD28+γδ T cells had reduced levels of IFN-γ and, hence, were less activated compared to CD28- cells. Based on these findings, we concluded that analyzing the PBMCs of LT recipients by CyTOF can predict the post-LT HCC recurrence. The distinct immune features can stratify patients with the risk of HCC recurrence at 3 weeks after LT, which will help clinician in further management plan and improve the prognosis of patients. AJCR
Copyright © 2022.

Entities:  

Keywords:  Hepatocellular carcinoma; liver transplantation; mass cytometry

Year:  2022        PMID: 36225628      PMCID: PMC9548010     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  48 in total

1.  The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Authors:  Hiromi Imamichi; Richard A Lempicki; Joseph W Adelsberger; Rebecca B Hasley; Alice Rosenberg; Gregg Roby; Catherine A Rehm; Amy Nelson; Sonya Krishnan; Mark Pavlick; Christian J Woods; Michael W Baseler; H Clifford Lane
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

2.  Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria.

Authors:  Victor M Zaydfudim; Neeta Vachharajani; Goran B Klintmalm; William R Jarnagin; Alan W Hemming; Maria B Majella Doyle; Keith M Cavaness; William C Chapman; David M Nagorney
Journal:  Ann Surg       Date:  2016-10       Impact factor: 12.969

3.  Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers.

Authors:  Valentina Rosa Bertuzzo; Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Massimo Del Gaudio; Alessandro Cucchetti; Antonietta D'Errico-Grigioni; Rita Golfieri; Antonio Daniele Pinna
Journal:  Transplantation       Date:  2011-06-15       Impact factor: 4.939

4.  Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.

Authors:  Zhe Yang; Shuo Wang; Xin-Yao Tian; Qin-Fen Xie; Li Zhuang; Qi-Yong Li; Cheng-Ze Chen; Shu-Sen Zheng
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2020-06-07

5.  Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells.

Authors:  D E Speiser; M Migliaccio; M J Pittet; D Valmori; D Liénard; F Lejeune; P Reichenbach; P Guillaume; I Lüscher; J C Cerottini; P Romero
Journal:  Eur J Immunol       Date:  2001-02       Impact factor: 5.532

6.  Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm.

Authors:  Eli R Zunder; Rachel Finck; Gregory K Behbehani; El-Ad D Amir; Smita Krishnaswamy; Veronica D Gonzalez; Cynthia G Lorang; Zach Bjornson; Matthew H Spitzer; Bernd Bodenmiller; Wendy J Fantl; Dana Pe'er; Garry P Nolan
Journal:  Nat Protoc       Date:  2015-01-22       Impact factor: 13.491

Review 7.  Liver transplantation for hepatocellular carcinoma: Management after the transplant.

Authors:  Elizabeth C Verna; Yuval A Patel; Avin Aggarwal; Archita P Desai; Catherine Frenette; Anjana A Pillai; Reena Salgia; Anil Seetharam; Pratima Sharma; Courtney Sherman; Georgios Tsoulfas; Francis Y Yao
Journal:  Am J Transplant       Date:  2019-12-09       Impact factor: 8.086

8.  Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites.

Authors:  Francesco Dieli; Fabrizio Poccia; Martin Lipp; Guido Sireci; Nadia Caccamo; Caterina Di Sano; Alfredo Salerno
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

Review 9.  Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy.

Authors:  Weitao Zhang; Jiawei Li; Guisheng Qi; Guowei Tu; Cheng Yang; Ming Xu
Journal:  J Transl Med       Date:  2018-01-29       Impact factor: 5.531

10.  Peripheral blood CD4(+) cell ATP activity measurement to predict HCC recurrence post-DCD liver transplant.

Authors:  W Zhang; H Zhong; L Zhuang; J Yu; X Xu; W Wang; M Zhang; L Zhou; S Zheng
Journal:  Int J Clin Pract       Date:  2016-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.